Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Cytostatic Therapy | Research

Understanding changes in pulmonary function and functional status in breast cancer patients after systemic chemotherapy and radiotherapy: a prospective study

Authors: Alper Tuğral, Zeynep Arıbaş, Murat Akyol, Yeşim Bakar

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Respiratory complications in breast cancer (BC) patients after chemotherapy (CT) and radiotherapy (RT) have been well acquainted and these complications should be investigated to prevent secondary problems and/or improve BC patients’ clinical outcomes. Therefore, this study aimed to assess the potential acute effect of systemic chemotherapy and radiotherapy on respiratory function and functional status of patients with breast cancer.

Methods

A total of 25 BC patients who were candidates for systemic chemotherapy and radiotherapy were recruited after oncological examination and included in this study. Respiratory function and functional status were assessed with the Pulmonary Function Test (PFT) and the Six-Minute Walk Test (6MWT), respectively. Patients were assessed before CT (c0), after CT (c1), and after RT (r1).

Results

25 BC patients were assessed in c0 and c1 while only 15 out of 25 patients (60%) were assessed in r1. The actual values of Forced vital capacity (FVC) (t = 2.338, p =.028), Forced expiratory volume in 1s (FEV1 (t = 2.708, p =.012), and the forced expiratory flow of between 25% and 75% of vital capacity (FEF25-75%) (t = 2.200, p =.038) were found significantly different after systemic CT. Inspiratory (MIP) and expiratory (MEP) muscle strength also did not show a significant change from c0 to c1. A significant effect of the type of surgery was found (Wilks’ lambda, F [1, 19] = 6.561, p =.019, ηp2 = 0.25) between c0 and c1 in actual FVC value. The main effect of time was found significant in FVC (F [2, 28] = 4.840, p =.016, ηp2 = 0.25) from c0 to r1. Pairwise comparisons with Bonferroni correction showed that there was a significant difference between c0 and r1 (p =.037).

Discussion

The present study showed decreased FVC and FEV1 actual values and percent predicted rates from baseline to the completion of treatment. Since the interactional effect of the type of surgery was significant, we suggest that clinical and demographic factors such as age should be considered when interpreting the early changes in PFT. In addition, the significant linear trend of decreasing in some specific outcomes in respiratory function also highlighted the need for continuous monitoring of potential respiratory problems in patients with BC from baseline to the completion of chemotherapy and radiotherapy.
Literature
1.
go back to reference Society AC. How common is breast cancer? Breast Cancer Stat, 20190. 2020. Society AC. How common is breast cancer? Breast Cancer Stat, 20190. 2020.
2.
go back to reference Wang L, Li J, Wang T, Xie Y, Fan Z, He Y, et al. Long-term recurrence rate and survival in different aged patients with breast cancer undergoing breast conserving therapy. Zhonghua Wai Ke Za Zhi. 2021;59(2):127–33.PubMed Wang L, Li J, Wang T, Xie Y, Fan Z, He Y, et al. Long-term recurrence rate and survival in different aged patients with breast cancer undergoing breast conserving therapy. Zhonghua Wai Ke Za Zhi. 2021;59(2):127–33.PubMed
4.
go back to reference Shannon VR, Price KJ. Pulmonary complications of cancer therapy. Anesthesiol Clin. 1998;16(3):563–86.CrossRef Shannon VR, Price KJ. Pulmonary complications of cancer therapy. Anesthesiol Clin. 1998;16(3):563–86.CrossRef
5.
go back to reference Ding L, Wang L, Yin J, Fan Z, He Z. Effects of neoadjuvant chemotherapy on respiratory function in patients with breast cancer. Chin J Cancer Res. 2020;32(1):36–42.CrossRefPubMedPubMedCentral Ding L, Wang L, Yin J, Fan Z, He Z. Effects of neoadjuvant chemotherapy on respiratory function in patients with breast cancer. Chin J Cancer Res. 2020;32(1):36–42.CrossRefPubMedPubMedCentral
6.
go back to reference Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, et al. Changes in pulmonary function and influencing factors after high-dose intrathoracic radio (chemo) therapy. Strahlenther Onkol. 2017;193(2):125–31.CrossRefPubMed Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, et al. Changes in pulmonary function and influencing factors after high-dose intrathoracic radio (chemo) therapy. Strahlenther Onkol. 2017;193(2):125–31.CrossRefPubMed
7.
go back to reference Dimopoulou I, Galani H, Dafni U, Samakovli A, Roussos C, Dimopoulos MA. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer. 2002;15(2):452–8.CrossRef Dimopoulou I, Galani H, Dafni U, Samakovli A, Roussos C, Dimopoulos MA. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer. 2002;15(2):452–8.CrossRef
8.
go back to reference Suesada MM, Carvalho HA, ALPd A, Salge JM, Stuart SR, Takagaki TY. Impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. J Bras Pneumol. 2018;44(6):469–76.CrossRefPubMedPubMedCentral Suesada MM, Carvalho HA, ALPd A, Salge JM, Stuart SR, Takagaki TY. Impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. J Bras Pneumol. 2018;44(6):469–76.CrossRefPubMedPubMedCentral
9.
go back to reference Jaén J, Vázquez G, Alonso E, León A, Guerrero R, Almansa JF. Changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2006;65(5):1381–8.CrossRefPubMed Jaén J, Vázquez G, Alonso E, León A, Guerrero R, Almansa JF. Changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2006;65(5):1381–8.CrossRefPubMed
10.
go back to reference Krengli M, Sacco M, Loi G, Masini L, Ferrante D, Gambaro G, et al. Pulmonary changes after radiotherapy for conservative treatment of breast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2008;70(5):1460–7.CrossRefPubMed Krengli M, Sacco M, Loi G, Masini L, Ferrante D, Gambaro G, et al. Pulmonary changes after radiotherapy for conservative treatment of breast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2008;70(5):1460–7.CrossRefPubMed
11.
go back to reference Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6(2):153–61.CrossRefPubMed Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6(2):153–61.CrossRefPubMed
12.
go back to reference Hernberg M, Virkkunen P, Maasilta P, Keyriläinen J, Blomqvist C, Bergh J, et al. Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. Int J Radiat Oncol Biol Phys. 2002;52(1):128–36.CrossRefPubMed Hernberg M, Virkkunen P, Maasilta P, Keyriläinen J, Blomqvist C, Bergh J, et al. Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. Int J Radiat Oncol Biol Phys. 2002;52(1):128–36.CrossRefPubMed
13.
go back to reference Järvenpää R, Holli K, Pitkänen M, Hyödynmaa S, Rajala J, Lahtela S-L, et al. Radiological pulmonary findings after breast cancer irradiation: a prospective study. Acta Oncol. 2006;45(1):16–22.CrossRefPubMed Järvenpää R, Holli K, Pitkänen M, Hyödynmaa S, Rajala J, Lahtela S-L, et al. Radiological pulmonary findings after breast cancer irradiation: a prospective study. Acta Oncol. 2006;45(1):16–22.CrossRefPubMed
14.
go back to reference Nishioka A, Ogawa Y, Hamada N, Terashima M, Inomata T, Yoshida S. Analysis of radiation pneumonitis and radiation-induced lung fibrosis in breast cancer patients after breast conservation treatment. Oncol Rep. 1999;6(3):513–20.PubMed Nishioka A, Ogawa Y, Hamada N, Terashima M, Inomata T, Yoshida S. Analysis of radiation pneumonitis and radiation-induced lung fibrosis in breast cancer patients after breast conservation treatment. Oncol Rep. 1999;6(3):513–20.PubMed
15.
go back to reference Ooi G, Kwong D, Ho J, Lock D, Chan F, Lam W, et al. Pulmonary sequelae of treatment for breast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2001;50(2):411–9.CrossRefPubMed Ooi G, Kwong D, Ho J, Lock D, Chan F, Lam W, et al. Pulmonary sequelae of treatment for breast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2001;50(2):411–9.CrossRefPubMed
16.
go back to reference Hyatt RE, Scanlon PD, Nakamura M. Interpretation of pulmonary function tests. 4th ed. Lippincott Williams & Wilkins; 2014. Hyatt RE, Scanlon PD, Nakamura M. Interpretation of pulmonary function tests. 4th ed. Lippincott Williams & Wilkins; 2014.
17.
go back to reference Elm Ev. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Inter Med. 2007;147:573–7.CrossRef Elm Ev. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Inter Med. 2007;147:573–7.CrossRef
18.
go back to reference Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1). Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1).
19.
go back to reference Agarwala P, Salzman SH. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest. 2020;157(3):603–11.CrossRefPubMed Agarwala P, Salzman SH. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest. 2020;157(3):603–11.CrossRefPubMed
20.
go back to reference Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer patients. Int J Sports Med. 2013:631–6. Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer patients. Int J Sports Med. 2013:631–6.
21.
go back to reference Faul F, Erdfelder E, Lang A-G, Buchner A. G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRefPubMed Faul F, Erdfelder E, Lang A-G, Buchner A. G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRefPubMed
22.
go back to reference Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93(23):1806–11.CrossRefPubMed Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93(23):1806–11.CrossRefPubMed
23.
go back to reference Braun TP, Szumowski M, Levasseur PR, Grossberg AJ, Zhu X, Agarwal A, et al. Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS ONE. 2014;9(9):e106489.CrossRefPubMedPubMedCentralADS Braun TP, Szumowski M, Levasseur PR, Grossberg AJ, Zhu X, Agarwal A, et al. Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS ONE. 2014;9(9):e106489.CrossRefPubMedPubMedCentralADS
24.
go back to reference Ruiz-Casado A, Alvarez-Bustos A, de Pedro CG, Mendez-Otero M, Romero-Elias M. Cancer-related fatigue in breast cancer survivors: a review. Clin Breast Cancer. 2021;21(1):10–25.CrossRefPubMed Ruiz-Casado A, Alvarez-Bustos A, de Pedro CG, Mendez-Otero M, Romero-Elias M. Cancer-related fatigue in breast cancer survivors: a review. Clin Breast Cancer. 2021;21(1):10–25.CrossRefPubMed
25.
go back to reference Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, et al. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol. 2008;104(1):57–66.CrossRefPubMed Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, et al. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol. 2008;104(1):57–66.CrossRefPubMed
26.
go back to reference Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest. 1996;110(1):289–92.CrossRefPubMed Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest. 1996;110(1):289–92.CrossRefPubMed
27.
go back to reference Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother. 1997;31(12):1471–4.CrossRefPubMed Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother. 1997;31(12):1471–4.CrossRefPubMed
28.
go back to reference Yoshioka K, Abe M, Shiko Y, Koshikawa K, Kawasaki Y, Iwasawa S, et al. Clinical characteristics and risk factors of Lung Injury Induced by Nab-Paclitaxel. Drug Des Devel Ther. 2022;16:759–67.CrossRefPubMedPubMedCentral Yoshioka K, Abe M, Shiko Y, Koshikawa K, Kawasaki Y, Iwasawa S, et al. Clinical characteristics and risk factors of Lung Injury Induced by Nab-Paclitaxel. Drug Des Devel Ther. 2022;16:759–67.CrossRefPubMedPubMedCentral
29.
go back to reference Rostkowska E, Bak M, Samborski W. Body posture in women after mastectomy and its changes as a result of rehabilitation. Adv Med Sci. 2006;51(2):287–97.PubMed Rostkowska E, Bak M, Samborski W. Body posture in women after mastectomy and its changes as a result of rehabilitation. Adv Med Sci. 2006;51(2):287–97.PubMed
30.
go back to reference Kadoyama K, Kuwahara A, Yamamori M, Brown J, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res. 2011;30(1):1–6.CrossRef Kadoyama K, Kuwahara A, Yamamori M, Brown J, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res. 2011;30(1):1–6.CrossRef
31.
go back to reference Ponce MC, Sankari A, Sharma S, Pulmonary Function T. 2022 Sep 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023–. PMID: 29493964. Ponce MC, Sankari A, Sharma S, Pulmonary Function T. 2022 Sep 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023–. PMID: 29493964.
32.
go back to reference Cantarero-Villanueva I, Postigo-Martin P, Granger CL, Waterland J, Galiano-Castillo N, Denehy L. The minimal clinically important difference in the treadmill six-minute walk test in active women with breast cancer during and after oncological treatments. Disabil Rehabil. 2023;45(5):871–8.CrossRefPubMed Cantarero-Villanueva I, Postigo-Martin P, Granger CL, Waterland J, Galiano-Castillo N, Denehy L. The minimal clinically important difference in the treadmill six-minute walk test in active women with breast cancer during and after oncological treatments. Disabil Rehabil. 2023;45(5):871–8.CrossRefPubMed
33.
go back to reference But-Hadzic J, Dervisevic M, Karpljuk D, Videmsek M, Dervisevic E, Paravlic A, et al. Six-minute walk distance in breast cancer survivors—A systematic review with meta-analysis. Int J Environ Res Public Health. 2021;18(5):2591.CrossRefPubMedPubMedCentral But-Hadzic J, Dervisevic M, Karpljuk D, Videmsek M, Dervisevic E, Paravlic A, et al. Six-minute walk distance in breast cancer survivors—A systematic review with meta-analysis. Int J Environ Res Public Health. 2021;18(5):2591.CrossRefPubMedPubMedCentral
34.
go back to reference Ying L, Yahng JMJ, Fisher M, Simons K, Nightingale S. Walking the boundaries: using the 6-min walk test for accurate assessment of the level of fitness in breast clinic outpatients. ANZ J Surg. 2020;90(6):1141–5.CrossRefPubMed Ying L, Yahng JMJ, Fisher M, Simons K, Nightingale S. Walking the boundaries: using the 6-min walk test for accurate assessment of the level of fitness in breast clinic outpatients. ANZ J Surg. 2020;90(6):1141–5.CrossRefPubMed
35.
go back to reference Akyol M, Tuğral A, Arıbaş Z, Bakar Y. Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study. Breast Cancer. 2023;30(4):617–26.CrossRefPubMed Akyol M, Tuğral A, Arıbaş Z, Bakar Y. Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study. Breast Cancer. 2023;30(4):617–26.CrossRefPubMed
36.
go back to reference Lewandowska A, Rudzki G, Lewandowski T, Próchnicki M, Rudzki S, Laskowska B, et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health. 2020;17(19):6938.CrossRefPubMedPubMedCentral Lewandowska A, Rudzki G, Lewandowski T, Próchnicki M, Rudzki S, Laskowska B, et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health. 2020;17(19):6938.CrossRefPubMedPubMedCentral
37.
go back to reference Minor GI, Yashar CM, Spanos WJ Jr, Jose BO, Silverman CL, Carrascosa LA, et al. The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy. Breast J. 2006;12(1):48–52.CrossRefPubMed Minor GI, Yashar CM, Spanos WJ Jr, Jose BO, Silverman CL, Carrascosa LA, et al. The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy. Breast J. 2006;12(1):48–52.CrossRefPubMed
38.
go back to reference Käsmann L, Dietrich A, Staab-Weijnitz CA, Manapov F, Behr J, Rimner A, et al. Radiation-induced lung toxicity–cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol. 2020;15(1):1–16.CrossRef Käsmann L, Dietrich A, Staab-Weijnitz CA, Manapov F, Behr J, Rimner A, et al. Radiation-induced lung toxicity–cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol. 2020;15(1):1–16.CrossRef
40.
go back to reference Karlsen J, Tandstad T, Sowa P, Salvesen Ø, Stenehjem JS, Lundgren S, et al. Pneumonitis and fibrosis after breast cancer radiotherapy: occurrence and treatment-related predictors. Acta Oncol. 2021;60(12):1651–8.CrossRefPubMed Karlsen J, Tandstad T, Sowa P, Salvesen Ø, Stenehjem JS, Lundgren S, et al. Pneumonitis and fibrosis after breast cancer radiotherapy: occurrence and treatment-related predictors. Acta Oncol. 2021;60(12):1651–8.CrossRefPubMed
41.
go back to reference Cilla S, Macchia G, Romano C, Morabito VE, Boccardi M, Picardi V, et al. Challenges in lung and heart avoidance for postmastectomy breast cancer radiotherapy: is automated planning the answer? Med Dosim. 2021;46(3):295–303.CrossRefPubMed Cilla S, Macchia G, Romano C, Morabito VE, Boccardi M, Picardi V, et al. Challenges in lung and heart avoidance for postmastectomy breast cancer radiotherapy: is automated planning the answer? Med Dosim. 2021;46(3):295–303.CrossRefPubMed
42.
go back to reference AlSaeed EF, Balaraj FK, Tunio MA. Changes in pulmonary function tests in breast carcinoma patients treated with locoregional post-mastectomy radiotherapy: results of a pilot study. Breast Cancer (Dove Med Press. 2017;9:375–81.PubMed AlSaeed EF, Balaraj FK, Tunio MA. Changes in pulmonary function tests in breast carcinoma patients treated with locoregional post-mastectomy radiotherapy: results of a pilot study. Breast Cancer (Dove Med Press. 2017;9:375–81.PubMed
43.
go back to reference Erven K, Weltens C, Nackaerts K, Fieuws S, Decramer M, Lievens Y. Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Biol Phys. 2012;82(2):701–7.CrossRefPubMed Erven K, Weltens C, Nackaerts K, Fieuws S, Decramer M, Lievens Y. Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Biol Phys. 2012;82(2):701–7.CrossRefPubMed
44.
go back to reference Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non–small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys. 2005;62(3):639–44.CrossRefPubMed Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non–small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys. 2005;62(3):639–44.CrossRefPubMed
Metadata
Title
Understanding changes in pulmonary function and functional status in breast cancer patients after systemic chemotherapy and radiotherapy: a prospective study
Authors
Alper Tuğral
Zeynep Arıbaş
Murat Akyol
Yeşim Bakar
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02890-5

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine